NTLA Intellia Therapeutics tops Q4 2025 EPS estimates posts 169 percent yearoveryear revenue growth as shares edge slightly lower TARS Tarsus Pharmaceuticals reports 1467 percent Q4 2025 revenue growth but wider than expected EPS losses push shares 16 percent lower The real value proposition of Cardio Diagn CDIO stock 164 20260511 Trupanion TRUP Stock Valuation Perspective Eye on Rally 20260420 Duff Phelps DPG Stock Is It Losing Momentum Quickly On the Radar 20260420